Feeds:
Posts
Comments

Posts Tagged ‘prolia’

*****

Impactiviti Daily will not be published next week, as I will be attending the annual Society of Pharmaceutical and Biotech Trainers conference (SPBT) in Orlando.

TODAY’S NEWS:

As the pre-ASCO news heats up, the big headline will be leukemia treatments – specifically, BMS‘ Sprycel and Novartis‘ Gleevec and Tasigna (just inTasigna shown superior to Gleevec in slowing CML: 18-month results). Treatments in this class, by the way, are something near miracle drugs. They’ve totally revolutionized blood cancer treatments. In related news, Novartis’ Afinitor (approved for kidney cancer) meets goals in a trial for pancreatic cancer.

Why should you be interested in a “nanosponge”? Well, there’s this – Scientists have found that a delivery system based on a technique called nanosponge is three to five times more effective at reducing tumor growth than direct injectionmore

Will Amgen‘s new osteoporosis drug Prolia find its true home in oncology treatment? – The company has also applied for FDA approval to market the drug to breast cancer and prostate cancer patients who are undergoing a hormone treatment that weakens their bones. What’s more, the company is conducting tests designed to show that Prolia prevents cancer from spreading to the bones — an indication that could push sales of the drug to as much as $6 billion annually, some analysts predictmore Also – huge sales force push for Prolia.

20% of high school students abuse prescription drugs. Wow – sobering.

RECOMMENDED

Simulations/Gaming. Live training simulations, digital sims (eLearning) and on-line games – our partner network has the expertise you need.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

How to reduce e-mail ping-pong. You know all that back-and-forth? Here’s a way to undercut it at the start!

JUST FOR FUN

See-through animals. Ten of them. Amazing.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS:

Amgen finally gets approval for Prolia – After months of delay, Amgen finally won FDA approval for Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures. The endorsement is a big boost for the biotech, which has been counting on Prolia to reverse a series of setbacks over the past few years, notably a decline in sales of some of its largest-selling products, Aranesp and Enbrelmore

Encouraging early-early-early result? Sure. Overly optimistic headline? Of course. New vaccine “could eliminate breast cancer.” Sally Church gives us some good cautionary words about over-hyping such results.

Biogen sues multiple rivals over MS drug – seeks royalties. I’m sure the lawyers, at least, are happy about this development.

RECOMMENDED

Territory Management Training. We’ve got the vendor/partners you need for this – contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

JOB OPENINGS

Sales and Account Manager, Training Agency serving Life Sciences (Massachusetts), experience required. From the Impactiviti Job Board.

PLUS

Looking Forward to the SPBT Conference – here’s what I’ll be doing, and the workshops that look appealing. Will I see you there? Download my digital business card (see linked post) and let’s get together in Orlando! (SPBT = Society of Pharmaceutical and Biotech Trainers)

JUST FOR FUN

16 Thin Buildings. Actually, I’d prefer to see one thinner consultant, in the mirror. Sigh.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »